Agilent Technologies Inc. has introduced a new series of HaloPlex next-generation sequencing panels targeting specific disease states.
Two catalog products, the HaloPlex Cancer Research Panel and the HaloPlex Cardiomyopathy Research Panel, plus five predesigned research panels for arrhythmia, ICCG genomic regions, X chromosome, Noonan syndrome, and connective tissue disorders are now available.
Used in combination with Agilent’s SureDesign and SureCall software, the new panels enable laboratories to perform integrated data analysis, mapping and reporting with greater confidence, speed and flexibility.
“With the adoption of desktop sequencing, clinical research laboratories are increasingly interested in panels with predesigned content for routine analysis,” said Dr. Berivan Baskin, FACMG, FCCMG, clinical molecular geneticist at Uppsala University Hospital, who worked with Agilent to develop the panels.
Dr. Baskin continued, “These new HaloPlex panels, combined with Agilent’s analysis software, provide comprehensive content with high levels of sensitivity and specificity.”
“Clinical research laboratories commonly lack the time and resources necessary to individually define disease-related genes and incorporate them into their own custom sequencing panels,” said Jacob Thaysen, vice president and general manager of Agilent’s Genomics Solutions Division.
Thaysen continued, “So we have been working closely with industry experts to develop these targeted disease panels to help these laboratories dramatically improve their workflows and research outcomes.”
HaloPlex target-enrichment solutions combine the speed and specificity of polymerase chain reaction-based systems with the scalability and capture-size flexibility of solution-based hybridization formats, eliminating the need for library preparation.
This streamlined sequence-selective solution for next-generation sequencing helps to remove bottlenecks associated with targeted resequencing and eliminate the need for expensive, dedicated instrumentation or laborious protocols.
SureDesign and SureCall software programs are an integral part of Agilent’s complete solutions for next-generation sequencing target enrichment.
SureDesign increases flexibility by allowing HaloPlex panel users to develop custom panels and incorporate additional predesigned genes/regions of interest to suit their laboratory’s individual needs.
SureCall significantly reduces the data analysis hurdles faced by researchers, enabling simple and intuitive variant calling.